Integrated Filing — IndAS



General information about company
Scrip Code 532305
NSE Symbol INDSWFTLAB
MSEI Symbol NOTLISTED
ISIN INE915B01019
Name of company IND-SWIFT LABORATORIES LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-Apr-2024
Date of end of financial year 31-Mar-2025
Date of board meeting when results were approved 11-Aug-2025
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 01-Aug-2025
Description of presentation currency INR (in Actuals)
Reporting Type Quarterly
Reporting Quarter Fourth quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Audited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Audited
Segment Reporting Single segment
Description of single segment PHARMACEUTICALS
Start date and time of board meeting 11-Aug-2025   17:30:00
End date and time of board meeting 11-Aug-2025   19:30:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 2025-02-13
Indicate Company website link for updated RPT policy of the Company https://www.indswiftlabs.com/wp-content/uploads/2025/05/Related_Party_Policy_01022025.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? Yes
No. of times funds raised during the quarter 1
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
No such default on loan



Financial Results Ind-AS
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Part I Blue color marked fields are non-mandatory. For Consolidated Results, if the company has no figures for 3 months / 6 months ended, in such case zero shall be inserted in the said column.
1 Income
Revenue from operations 1447464000 5496467000
Other income 44127000 812749000
Total income 1491591000 6309216000
2 Expenses
(a) Cost of materials consumed 317741000 2245596000
(b) Purchases of stock-in-trade 339111000 708036000
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade 42272000 -103623000
(d) Employee benefit expense 307870000 1153348000
(e) Finance costs -267572000 29184000
(f) Depreciation, depletion and amortisation expense 74373000 244793000
(f) Other Expenses
1 Other Expenses 575132000 1622497000
Total other expenses 575132000 1622497000
Total expenses 1388927000 5899831000
3 Total profit before exceptional items and tax 102664000 409385000
4 Exceptional items 2158796000 2232042000
5 Total profit before tax 2261460000 2641427000
6 Tax expense
7 Current tax 40785000 40785000
8 Deferred tax 39791000 39791000
9 Total tax expenses 80576000 80576000
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0 0
11 Net Profit Loss for the period from continuing operations 2180884000 2560851000
12 Profit (loss) from discontinued operations before tax 0 0
13 Tax expense of discontinued operations 0 0
14 Net profit (loss) from discontinued operation after tax 0 0
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0 0
16 Total profit (loss) for period 2180884000 2560851000
17 Other comprehensive income net of taxes 172255000 172255000
18 Total Comprehensive Income for the period 2353139000 2733106000
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 687436000 687436000
Face value of equity share capital 10 10
27 Details of debt securities
22 Reserves excluding revaluation reserve 11640781000
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 32.34 38.08
Diluted earnings (loss) per share from continuing operations 29.51 36
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 32.34 38.08
Diluted earnings (loss) per share from continuing and discontinued operations 29.51 36
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results Textual Information(1)



Disclosure of notes on financial results
Textual Information(1) Please refer notes as given in the pdf disclosure. Also note that Ind Swift Limited has been amalgamated with Ind Swift Laboratories Limited. Attached results are of merged entity and hence the figures are not directly comparable with the previous disclosed figures.



Remarks
Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities
Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-Apr-2024
Date of end of reporting period 31-Mar-2025
Whether results are audited or unaudited Audited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 2588370000
Capital work-in-progress
Investment property 22532000
Goodwill 0
Other intangible assets 106813000
Intangible assets under development
Biological assets other than bearer plants
Investments accounted for using equity method
Non-current financial assets
Non-current investments 2295458000
Trade receivables, non-current 0
Loans, non-current 735440000
Other non-current financial assets 20270000
Total non-current financial assets 3051168000
Deferred tax assets (net) 446342000
Other non-current assets 67983000
Total non-current assets 6283208000
2 Current assets
Inventories 1072493000
Current financial asset
Current investments 393660000
Trade receivables, current 1602294000
Cash and cash equivalents 4130120000
Bank balance other than cash and cash equivalents 0
Loans, current 0
Other current financial assets 142390000
Total current financial assets 6268464000
Current tax assets (net)
Other current assets 596365000
Total current assets 7937322000
3 Non-current assets classified as held for sale
4 Regulatory deferral account debit balances and related deferred tax Assets
Total assets 14220530000
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 687436000
Other equity 10953345000
Total equity attributable to owners of parent 11640781000
Non controlling interest
Total equity 11640781000
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 225416000
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises
Total Trade payable
Other non-current financial liabilities 2271000
Total non-current financial liabilities 227687000
Provisions, non-current 113670000
Deferred tax liabilities (net)
Deferred government grants, Non-current
Other non-current liabilities 74916000
Total non-current liabilities 416273000
Current liabilities
Current financial liabilities
Borrowings, current 146211000
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 58735000
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 1045837000
Total Trade payable 1104572000
Other current financial liabilities 154000
Total current financial liabilities 1250937000
Other current liabilities 853470000
Provisions, current 18284000
Current tax liabilities (Net) 40785000
Deferred government grants, Current
Total current liabilities 2163476000
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 2579749000
Total equity and liabilites 14220530000
Disclosure of notes on assets and liabilities



Format for Reporting Segmenet wise Revenue, Results and Capital Employed along with the company results
Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-Jan-2025 01-Apr-2024
Date of end of reporting period 31-Mar-2025 31-Mar-2025
Whether accounts are audited or unaudited Audited Audited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income
Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-Jan-2025 01-Apr-2024
B Date of end of reporting period 31-Mar-2025 31-Mar-2025
C Whether results are audited or unaudited Audited Audited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
Total Amount of items that will not be reclassified to profit and loss
2 Income tax relating to items that will not be reclassified to profit or loss 0 0
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss -172255000 -172255000
5 Total Other comprehensive income 172255000 172255000



Cash flow statement, indirect
Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-Apr-2024
B Date of end of reporting period 31-Mar-2025
C Whether results are audited or unaudited Audited
D Nature of report standalone or consolidated Standalone
Part I Blue color marked fields are non-mandatory.
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 2641427000
Adjustments for reconcile profit (loss)
Adjustments for finance costs 0
Adjustments for decrease (increase) in inventories -431578000
Adjustments for decrease (increase) in trade receivables, current 968439000
Adjustments for decrease (increase) in trade receivables, non-current 0
Adjustments for decrease (increase) in other current assets -585828000
Adjustments for decrease (increase) in other non-current assets -287222000
Adjustments for other financial assets, non-current 0
Adjustments for other financial assets, current 0
Adjustments for other bank balances 0
Adjustments for increase (decrease) in trade payables, current 0
Adjustments for increase (decrease) in trade payables, non-current 0
Adjustments for increase (decrease) in other current liabilities -349312000
Adjustments for increase (decrease) in other non-current liabilities 0
Adjustments for depreciation and amortisation expense 244635000
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0
Adjustments for provisions, current 34705000
Adjustments for provisions, non-current 0
Adjustments for other financial liabilities, current 0
Adjustments for other financial liabilities, non-current 0
Adjustments for unrealised foreign exchange losses gains 0
Adjustments for dividend income 0
Adjustments for interest income 0
Adjustments for share-based payments 0
Adjustments for fair value losses (gains) 0
Adjustments for undistributed profits of associates 0
Other adjustments for which cash effects are investing or financing cash flow 0
Other adjustments to reconcile profit (loss) 0
Other adjustments for non-cash items -2232042000
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0
Total adjustments for reconcile profit (loss) -2638203000
Net cash flows from (used in) operations 3224000
Dividends received 0
Interest paid -391579000
Interest received -752849000
Income taxes paid (refund) 33493000
Other inflows (outflows) of cash 0
Net cash flows from (used in) operating activities -391539000
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0
Cash flows used in obtaining control of subsidiaries or other businesses 0
Other cash receipts from sales of equity or debt instruments of other entities 0
Other cash payments to acquire equity or debt instruments of other entities 0
Other cash receipts from sales of interests in joint ventures 0
Other cash payments to acquire interests in joint ventures 0
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0
Proceeds from sales of property, plant and equipment 385964000
Purchase of property, plant and equipment 644061000
Proceeds from sales of investment property -1258302000
Purchase of investment property 0
Proceeds from sales of intangible assets 0
Purchase of intangible assets 0
Proceeds from sales of intangible assets under development 0
Purchase of intangible assets under development 0
Proceeds from sales of goodwill 0
Purchase of goodwill 0
Proceeds from biological assets other than bearer plants 0
Purchase of biological assets other than bearer plants 0
Proceeds from government grants 0
Proceeds from sales of other long-term assets 0
Purchase of other long-term assets 0
Cash advances and loans made to other parties 0
Cash receipts from repayment of advances and loans made to other parties 0
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0
Dividends received 0
Interest received 419703000
Income taxes paid (refund) 0
Other inflows (outflows) of cash 0
Net cash flows from (used in) investing activities -1096696000
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0
Payments from changes in ownership interests in subsidiaries 0
Proceeds from issuing shares 0
Proceeds from issuing other equity instruments 926341000
Payments to acquire or redeem entity's shares 0
Payments of other equity instruments 0
Proceeds from exercise of stock options 0
Proceeds from issuing debentures notes bonds etc 0
Proceeds from borrowings 275972000
Repayments of borrowings 15885000
Payments of lease liabilities -7023000
Dividends paid 0
Interest paid 419080000
Income taxes paid (refund) 32168000
Other inflows (outflows) of cash 0
Net cash flows from (used in) financing activities 742203000
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes -746032000
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0
Net increase (decrease) in cash and cash equivalents -746032000
Cash and cash equivalents cash flow statement at beginning of period 4876152000
Cash and cash equivalents cash flow statement at end of period 4130120000





Details of Impact of Audit Qualification
Whether results are audited or unaudited Audited
Declaration of unmodified opinion or statement on impact of audit qualification Declaration of unmodified opinion
Auditor's opinion
Declaration pursuant to Regulation 33 (3) (d) of SEBI (LODR) Regulation, 2015: The company declares that its Statutory Auditor/s have issued an Audit Report with unmodified opinion for the period on Standalone results Yes
Sr No. Audit firm's name Whether the firm holds a valid peer review certificate issued by Peer Review Board of ICAI Certificate valid upto
1 RATTAN KAUR AND ASSOCIATES Yes 31-Jan-2027


Statement on Deviation or Variation for proceeds of Public Issue, Rights Issue, Preferential Issue, Qualified Institutions Placement Etc. (1)
Mode of Fund Raising Preferential Issues
Description of mode of fund raising (Applicable in case of others is selected)
Date of Raising Funds 30-Aug-2024
Amount Raised 9264000
Report filed for Quarter ended 31-Mar-2025
Monitoring Agency Applicable
Monitoring Agency Name, if applicable tCARE Ratings Limited
Is there a Deviation / Variation in use of funds raised No
If yes, whether the same is pursuant to change in terms of a contract or objects, which was approved by the shareholders
If Yes, Date of shareholder Approval
Explanation for the Deviation / Variation NA
Comments of the Audit Committee after review NA
Comments of the auditors, if any NA
Sr. Original Object Modified Object, if any Original Allocation Modified allocation, if any Funds Utilised Amount of Deviation/Variation for the quarter according to applicable object Remarks if any
1 Expansion of Business of the Company or the Wholly Owned Subsidiaries NA 15000000 0 1437000 0
2 Investment in existing or to be acquired Subsidiaries NA 5000000 0 0 0
3 Working Capital for existing business NA 3960000 0 550000 0
4 General Corporate Purpose NA 7500000 0 7124000 0


Signatory Details
Name of signatory Pardeep Verma
Designation of person Company Secretary and Compliance Officer
Place Chandigarh
Date 11-Aug-2025




Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)
Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 IND-SWIFT LABORATORIES LIMITED ESSIX BIOSCIENCES LIMITED OTHER RP Investment 5000000000 As approved by Board/Shareholders 0 66231000 289632000 Textual Information(1)
2 IND-SWIFT LABORATORIES LIMITED ESSIX BIOSCIENCES LIMITED OTHER RP Sale of goods or services 1500000000 15000 372000 0 0 Textual Information(2)
3 IND-SWIFT LABORATORIES LIMITED ESSIX BIOSCIENCES LIMITED OTHER RP Purchase of goods or services 1500000000 15000 28792000 0 28446000 Textual Information(3)
4 IND-SWIFT LABORATORIES LIMITED SISLAX PHARMA PRIVATE LIMITED OTHER RP Sale of goods or services 100000000 1000 0 0 0 Textual Information(4)
5 IND-SWIFT LABORATORIES LIMITED SISLAX PHARMA PRIVATE LIMITED OTHER RP Any other transaction Receipt of Services/Creditors 100000000 1000 19569000 -2040000 1260000 Textual Information(5)
6 IND-SWIFT LABORATORIES LIMITED MOHALI GREEN ENVIRONMENT PRIVATE LIMITED OTHER RP Advance 50000000 500 2200000 0 2200000 Textual Information(6)
7 IND-SWIFT LABORATORIES LIMITED MOHALI GREEN ENVIRONMENT PRIVATE LIMITED OTHER RP Investment 500000000 5000 0 300000 300000 Textual Information(7)
8 IND-SWIFT LABORATORIES LIMITED IND-SWIFT LABORATORIES INC, USA WHOLLY OWNED SUBSIDIARY Sale of goods or services Being a wholly owned subsidiary, there is no requirement 76389000 65683000 18192000 Textual Information(8)
9 IND-SWIFT LABORATORIES LIMITED IND-SWIFT LABORATORIES INC, USA WHOLLY OWNED SUBSIDIARY Investment Being a wholly owned subsidiary, there is no requirement 0 54410000 54410000 Textual Information(9)
10 IND-SWIFT LABORATORIES LIMITED FORTUNE (INDIA) CONSTRUCTIONS LIMITED WHOLLY OWNED SUBSIDIARY Investment Being a wholly owned subsidiary, there is no requirement 0 724840000 724840000 Textual Information(10)
11 IND-SWIFT LABORATORIES LIMITED NAVRATTAN MUNJAL promoter Remuneration As approved by NRC/Board 23564000 0 5759000 Textual Information(11)
12 IND-SWIFT LABORATORIES LIMITED HIMANSHU JAIN promoter Remuneration As approved by NRC/Board 17613000 0 3740000 Textual Information(12)
13 IND-SWIFT LABORATORIES LIMITED RISHAV MEHTA promoter Remuneration As approved by NRC/Board 9412000 0 2346000 Textual Information(13)
14 IND-SWIFT LABORATORIES LIMITED SAHIL MUNJAL promoter Remuneration As approved by NRC/Board 10793000 0 3816000 Textual Information(14)
15 IND-SWIFT LABORATORIES LIMITED GAGAN AGGARWAL CFO Remuneration As approved by NRC/Board 1919000 0 0 Textual Information(15)
16 IND-SWIFT LABORATORIES LIMITED GAGAN AGGARWAL CFO Any other transaction Loans & Advances As approved by NRC/Board 0 1275000 1275000 Textual Information(16)
17 IND-SWIFT LABORATORIES LIMITED PARDEEP VERMA Company Secretary Remuneration As approved by NRC/Board 2123000 0 0 Textual Information(17)
18 IND-SWIFT LABORATORIES LIMITED PARDEEP VERMA Company Secretary Any other transaction Loans & Advances As approved by NRC/Board 0 421000 421000 Textual Information(18)
19 IND-SWIFT LABORATORIES LIMITED INDIS HEALTHCARE LLP Joint venture Investment 100000000 Within the maximum limit as approved by the Board 0 25000000 25000000 Textual Information(19)
20 IND-SWIFT LABORATORIES LIMITED INDIS HEALTHCARE LLP Joint venture Sale of goods or services 500000000 Within the maximum limit as approved by the Board 9165000 6054000 17779000 Textual Information(20)
21 IND-SWIFT LABORATORIES LIMITED MJM REMEDIES PRIVATE LIMITED Subsidiary Investment 5000000 Within the maximum limit as approved by the Board 0 1275000 1275000 Textual Information(21)
22 IND-SWIFT LABORATORIES LIMITED MJM REMEDIES PRIVATE LIMITED Subsidiary Sale of goods or services 100000000 1000 0 400000 400000 Textual Information(22)
23 IND-SWIFT LABORATORIES LIMITED ELAN VITAL DRUG STORE LLC OTHER RP Sale of goods or services 250000000 2500 30361000 8139000 30666000 Textual Information(23)
24 IND-SWIFT LABORATORIES LIMITED CHDMM TIBBI OMEHTA OTHER RP Sale of goods or services 50000000 500 8591000 28953000 36625000 Textual Information(24)
25 IND-SWIFT LABORATORIES LIMITED ELAN VITAL DRUG STORE LLC OTHER RP Purchase of goods or services 250000000 2500 2826000 0 0 Textual Information(25)
26 IND-SWIFT LABORATORIES LIMITED GOPAL MUNJAL OTHER RP Any other transaction Advance against Salary In terms with HR Policy 0 34579000 34579000 Textual Information(26)
27 IND-SWIFT LABORATORIES LIMITED S.R MEHTA OTHER RP Any other transaction Advance against Salary In terms with HR Policy 0 36319000 36319000 Textual Information(27)
28 IND-SWIFT LABORATORIES LIMITED VR MEHTA OTHER RP Any other transaction Advance against Salary In terms with HR Policy 0 35618000 35618000 Textual Information(28)
29 IND-SWIFT LABORATORIES LIMITED MUNJAL JAIN ESTATES PVT LTD OTHER RP Loan 1000 2453000 53764000 51311000 Textual Information(29)
30 IND-SWIFT LABORATORIES LIMITED MUNJAL JAIN ESTATES PVT LTD OTHER RP Interest paid 1000 5576000 0 0 Textual Information(30)
31 IND-SWIFT LABORATORIES LIMITED SWIFT FUNDAMENTAL RESEARCH & EDUCATION SOCIETY OTHER RP Advance 7000 0 628924000 628924000 Textual Information(31)
Total value of transaction during the reporting period 251718000



Text Block
Textual Information(1) Opening figures have been regrouped pursuant to merger. Change in closing value is due to fair value change.
Textual Information(2) Opening figures have been regrouped pursuant to merger.
Textual Information(3) Opening figures have been regrouped pursuant to merger.
Textual Information(4) Opening figures have been regrouped pursuant to merger.
Textual Information(5) Opening figures have been regrouped pursuant to merger.
Textual Information(6) Opening figures have been regrouped pursuant to merger.
Textual Information(7) Opening figures have been regrouped pursuant to merger.
Textual Information(8) Opening figures have been regrouped pursuant to merger.
Textual Information(9) Opening figures have been regrouped pursuant to merger.
Textual Information(10) Opening figures have been regrouped pursuant to merger.
Textual Information(11) Opening figures have been regrouped pursuant to merger.
Textual Information(12) Opening figures have been regrouped pursuant to merger.
Textual Information(13) Opening figures have been regrouped pursuant to merger.
Textual Information(14) Opening figures have been regrouped pursuant to merger.
Textual Information(15) Opening figures have been regrouped pursuant to merger.
Textual Information(16) Opening figures have been regrouped pursuant to merger.
Textual Information(17) Opening figures have been regrouped pursuant to merger.
Textual Information(18) Opening figures have been regrouped pursuant to merger.
Textual Information(19) Opening figures have been regrouped pursuant to merger.
Textual Information(20) Opening figures have been regrouped pursuant to merger.
Textual Information(21) Opening figures have been regrouped pursuant to merger.
Textual Information(22) Opening figures have been regrouped pursuant to merger.
Textual Information(23) Opening figures have been regrouped pursuant to merger.
Textual Information(24) Opening figures have been regrouped pursuant to merger.
Textual Information(25) Opening figures have been regrouped pursuant to merger.
Textual Information(26) Opening figures have been regrouped pursuant to merger.
Textual Information(27) Opening figures have been regrouped pursuant to merger.
Textual Information(28) Opening figures have been regrouped pursuant to merger.
Textual Information(29) Opening figures have been regrouped pursuant to merger.
Textual Information(30) Opening figures have been regrouped pursuant to merger.
Textual Information(31) Opening figures have been regrouped pursuant to merger.